<DOC>
	<DOC>NCT01115855</DOC>
	<brief_summary>A study to compare the efficacy and safety of eplerenone in Japanese chronic heart failure patients with placebo.</brief_summary>
	<brief_title>Clinical Study Of Eplerenone In Japanese Patients With Chronic Heart Failure</brief_title>
	<detailed_description>The aim of this study was to show consistency with the EMPHASIS-HF trial (NCT00232180), which was defined as a HR of the primary endpoint of below 1.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Japanese chronic systolic heart failure patients with LVEF =&lt;30% by echocardiography and NYHA II or more Patients who receive standard therapy (Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, betablocker or diuretic) Patients with a myocardial infarction, stroke, cardiac surgery or percutaneous coronary intervention within 30 days prior to randomization. Patients with serum potassium &gt;5.0 mmol/L or eGFR &lt;30 ml/min/1.73 m2.</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>eplerenone</keyword>
	<keyword>Japanese</keyword>
</DOC>